vs
Side-by-side financial comparison of Meritage Homes CORP (MTH) and Insulet Corporation (PODD). Click either name above to swap in a different company.
Meritage Homes CORP is the larger business by last-quarter revenue ($1.4B vs $783.7M, roughly 1.8× Insulet Corporation). Meritage Homes CORP runs the higher net margin — 17.7% vs 13.0%, a 4.7% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (31.2% vs 10.5%). Insulet Corporation produced more free cash flow last quarter ($48.2M vs $-225.4M).
Meritage Homes Corporation is a publicly traded American real estate development company that constructs a variety of single-family detached homes across the United States. It is the fifth largest home builder in the United States, based on 2023 home sales. The company also develops active adult communities and luxury real estate in Arizona.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
MTH vs PODD — Head-to-Head
Income Statement — Q2 FY2022 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.4B | $783.7M |
| Net Profit | $250.1M | $101.6M |
| Gross Margin | 31.5% | 72.6% |
| Operating Margin | 23.5% | 18.7% |
| Net Margin | 17.7% | 13.0% |
| Revenue YoY | 10.5% | 31.2% |
| Net Profit YoY | 49.4% | 0.9% |
| EPS (diluted) | $6.77 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $783.7M | ||
| Q3 25 | — | $706.3M | ||
| Q2 25 | — | $649.1M | ||
| Q1 25 | — | $569.0M | ||
| Q4 24 | — | $597.5M | ||
| Q3 24 | — | $543.9M | ||
| Q2 24 | — | $488.5M | ||
| Q1 24 | — | $441.7M |
| Q4 25 | — | $101.6M | ||
| Q3 25 | — | $87.6M | ||
| Q2 25 | — | $22.5M | ||
| Q1 25 | — | $35.4M | ||
| Q4 24 | — | $100.7M | ||
| Q3 24 | — | $77.5M | ||
| Q2 24 | — | $188.6M | ||
| Q1 24 | — | $51.5M |
| Q4 25 | — | 72.6% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 69.7% | ||
| Q1 25 | — | 71.9% | ||
| Q4 24 | — | 72.1% | ||
| Q3 24 | — | 69.3% | ||
| Q2 24 | — | 67.7% | ||
| Q1 24 | — | 69.5% |
| Q4 25 | — | 18.7% | ||
| Q3 25 | — | 16.7% | ||
| Q2 25 | — | 18.7% | ||
| Q1 25 | — | 15.6% | ||
| Q4 24 | — | 18.3% | ||
| Q3 24 | — | 16.2% | ||
| Q2 24 | — | 11.2% | ||
| Q1 24 | — | 12.9% |
| Q4 25 | — | 13.0% | ||
| Q3 25 | — | 12.4% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 6.2% | ||
| Q4 24 | — | 16.9% | ||
| Q3 24 | — | 14.2% | ||
| Q2 24 | — | 38.6% | ||
| Q1 24 | — | 11.7% |
| Q4 25 | — | $1.42 | ||
| Q3 25 | — | $1.24 | ||
| Q2 25 | — | $0.32 | ||
| Q1 25 | — | $0.50 | ||
| Q4 24 | — | $1.38 | ||
| Q3 24 | — | $1.08 | ||
| Q2 24 | — | $2.59 | ||
| Q1 24 | — | $0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $272.1M | — |
| Total DebtLower is stronger | — | $930.8M |
| Stockholders' EquityBook value | $3.4B | $1.5B |
| Total Assets | $5.3B | $3.2B |
| Debt / EquityLower = less leverage | — | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $930.8M | ||
| Q3 25 | — | $934.9M | ||
| Q2 25 | — | $939.0M | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B | ||
| Q1 24 | — | $1.4B |
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $998.4M | ||
| Q1 24 | — | $790.7M |
| Q4 25 | — | $3.2B | ||
| Q3 25 | — | $3.0B | ||
| Q2 25 | — | $3.5B | ||
| Q1 25 | — | $3.5B | ||
| Q4 24 | — | $3.1B | ||
| Q3 24 | — | $3.0B | ||
| Q2 24 | — | $2.9B | ||
| Q1 24 | — | $2.6B |
| Q4 25 | — | 0.61× | ||
| Q3 25 | — | 0.68× | ||
| Q2 25 | — | 0.64× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | — | 1.21× | ||
| Q2 24 | — | 1.36× | ||
| Q1 24 | — | 1.72× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-219.0M | $183.3M |
| Free Cash FlowOCF − Capex | $-225.4M | $48.2M |
| FCF MarginFCF / Revenue | -16.0% | 6.2% |
| Capex IntensityCapex / Revenue | 0.5% | 17.2% |
| Cash ConversionOCF / Net Profit | -0.88× | 1.80× |
| TTM Free Cash FlowTrailing 4 quarters | — | $377.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $183.3M | ||
| Q3 25 | — | $125.7M | ||
| Q2 25 | — | $196.5M | ||
| Q1 25 | — | $63.8M | ||
| Q4 24 | — | $147.7M | ||
| Q3 24 | — | $98.5M | ||
| Q2 24 | — | $96.5M | ||
| Q1 24 | — | $87.6M |
| Q4 25 | — | $48.2M | ||
| Q3 25 | — | $100.1M | ||
| Q2 25 | — | $177.9M | ||
| Q1 25 | — | $51.5M | ||
| Q4 24 | — | $94.1M | ||
| Q3 24 | — | $71.8M | ||
| Q2 24 | — | $74.0M | ||
| Q1 24 | — | $65.5M |
| Q4 25 | — | 6.2% | ||
| Q3 25 | — | 14.2% | ||
| Q2 25 | — | 27.4% | ||
| Q1 25 | — | 9.1% | ||
| Q4 24 | — | 15.7% | ||
| Q3 24 | — | 13.2% | ||
| Q2 24 | — | 15.1% | ||
| Q1 24 | — | 14.8% |
| Q4 25 | — | 17.2% | ||
| Q3 25 | — | 3.6% | ||
| Q2 25 | — | 2.9% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 9.0% | ||
| Q3 24 | — | 4.9% | ||
| Q2 24 | — | 4.6% | ||
| Q1 24 | — | 5.0% |
| Q4 25 | — | 1.80× | ||
| Q3 25 | — | 1.43× | ||
| Q2 25 | — | 8.73× | ||
| Q1 25 | — | 1.80× | ||
| Q4 24 | — | 1.47× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | 0.51× | ||
| Q1 24 | — | 1.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MTH
| Home Building | $1.4B | 100% |
| Equity Method Investment Nonconsolidated Investee Or Group Of Investees | $9.8M | 1% |
| Financial Service | $5.1M | 0% |
| Land Closing | $3.4M | 0% |
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
